Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736059 | 0.84 | ALOX15 (0.37) | ALOX15LMNA | |
| SCHEMBL1734711 | 0.83 | ALOX15 (0.37) | ALOX15 | |
| SCHEMBL28483044 | 0.82 | DGAT1 (0.48) | DGAT1CA12CA2CA14LMNA | |
| SCHEMBL12746064 | 0.81 | ALOX15 (0.40) | ALOX15HIF1AEPAS1 | |
| SCHEMBL6434714 | 0.79 | ALOX15 (0.43) | ALOX15CA12CA2CA14LMNA | |
| SCHEMBL28483049 | 0.72 | DGAT1 (0.45) | DGAT1CA12CA2CA14LMNA | |
| SCHEMBL14624782 | 0.71 | TSHR (0.36) | ALOX15 | |
| SCHEMBL2829358 | 0.70 | DGAT1 (0.41) | DGAT1CA12CA2CA14 | |
| SCHEMBL3413681 | 0.69 | HSD17B10 (0.35) | — | |
| SCHEMBL12826838 | 0.69 | HSD17B10 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| US-7842687-B2 | Natural, synthetic or semi-synthetic crude harringtonines purified by chromatography and crystallization in which the solvent is water or lower C1-4 alkanol or an aqueous mixture of organic solvents; treatment of cancer through oral administration | CHEMGENEX PHARMACEUTICALS, INC. (AU) | 2010-11-30 | — | — | US | disclosed |